Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISKAZIDE vs ZEPATIER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Viskazide is a combination of pindolol (a non-cardioselective beta-blocker with intrinsic sympathomimetic activity) and hydrochlorothiazide (a thiazide diuretic). Pindolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, decreasing sodium and water reabsorption, leading to reduced plasma volume and blood pressure.
ZEPATIER is a fixed-dose combination of elbasvir, an HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. Elbasvir inhibits HCV NS5A, disrupting viral replication and assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein into mature viral proteins.
Management of hypertension
Treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults,Treatment of chronic HCV genotype 1 or 4 infection in pediatric patients 12 years of age and older or weighing at least 30 kg
Oral: 1 tablet (pindolol 10 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets once daily if needed.
One tablet (elbasvir 50 mg/grazoprevir 100 mg) orally once daily.
Terminal elimination half-life is 10-12 hours for the hydrochlorothiazide component and 4-6 hours for pindolol; clinical context: steady-state achieved in 2-3 days for pindolol and 3-5 days for hydrochlorothiazide.
Elbasvir: terminal half-life approximately 24 hours. Grazoprevir: terminal half-life approximately 31 hours. The prolonged half-lives support once-daily dosing and allow for sustained viral suppression.
For GFR 30-60 m L/min: use with caution, monitor BP. For GFR <30 m L/min: contraindicated (thiazide ineffective).
No dose adjustment required for any degree of renal impairment including end-stage renal disease on dialysis.
Child-Pugh A: no dose adjustment. Child-Pugh B: reduce dose (e.g., start at pindolol 5 mg + HCTZ 12.5 mg) and titrate slowly. Child-Pugh C: contraindicated.
Exacerbation of ischemic heart disease following abrupt discontinuation: Beta-blocker withdrawal may precipitate angina, myocardial infarction, or ventricular arrhythmias in patients with coronary artery disease. Therapy should be tapered gradually over 1-2 weeks.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity (hydrochlorothiazide) and no teratogenicity (pindolol). Second/third trimesters: Hydrochlorothiazide may cause fetal jaundice, thrombocytopenia, and electrolyte disturbances; pindolol may cause fetal bradycardia and hypoglycemia. Avoid use in pregnancy unless benefit outweighs risk.
ZEPATIER (grazoprevir/elbasvir) is contraindicated in pregnancy due to the ribavirin component in some regimens. Ribavirin is teratogenic in all trimesters, causing fetal malformations and embryolethality. Grazoprevir/elbasvir alone has no adequate human data, but animal studies show no teratogenicity. However, combination with ribavirin mandates avoidance in pregnancy.
VISKAZIDE contains pindolol (a nonselective beta-blocker with intrinsic sympathomimetic activity) and a thiazide diuretic. Titrate slowly in elderly; monitor for bradycardia, heart block, and electrolyte disturbances. Use with caution in asthma, COPD, and peripheral vascular disease. The ISA minimizes resting bradycardia but does not protect against bronchospasm. Check serum potassium, sodium, and uric acid periodically.
ZEPATIER (elbasvir/grazoprevir) is indicated for chronic HCV genotypes 1 or 4. Prior to initiation, test for NS5A resistance-associated substitutions (RASs) in genotype 1a. In patients with genotype 1a and baseline NS5A RASs, treatment duration is 16 weeks with ribavirin. Avoid in moderate to severe hepatic impairment (Child-Pugh B or C). Monitor hepatic function closely. Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) is contraindicated. Also contraindicated with OATP1B1/3 inhibitors (e.g., cyclosporine) and certain HIV protease inhibitors (e.g., atazanavir, darunavir, lopinavir). Grazoprevir increases serum creatinine due to OATP2B1 inhibition, but this does not reflect true renal function decline.
No interactions on record
No interactions on record
VISKAZIDE and ZEPATIER are distinct pharmacological agents. VISKAZIDE belongs to the Beta Blocker/Thiazide Diuretic Combination class and is primarily used for Management of hypertension. ZEPATIER belongs to the Direct-Acting Antiviral (HCV) class and is primarily used for Treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adultsTreatment of chronic HCV genotype 1 or 4 infection in pediatric patients 12 years of age and older or weighing at least 30 kg. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. VISKAZIDE carries a safety status of Category C, whereas ZEPATIER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Pindolol undergoes hepatic metabolism primarily via hydroxylation and conjugation; approximately 60-65% is metabolized, with 35-40% excreted unchanged in urine. Hydrochlorothiazide is not metabolized and is excreted unchanged in urine.
Elbasvir is metabolized primarily by CYP3A. Grazoprevir is metabolized primarily by CYP3A. Mild oxidation and glucuronidation are minor pathways.
Renal elimination (approximately 70% unchanged), with the remainder as inactive metabolites; biliary/fecal excretion is minor (<10%).
Elbasvir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Grazoprevir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Renal elimination is negligible for both.
Pindolol: 40-50% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
Elbasvir: ≥99.9% bound, primarily to albumin and α1-acid glycoprotein. Grazoprevir: 98.8% bound, primarily to albumin and α1-acid glycoprotein.
Pindolol: 1.2-2.0 L/kg indicating extensive tissue distribution; Hydrochlorothiazide: 3-4 L/kg suggesting wide distribution.
Elbasvir: apparent Vd approximately 4.5 L/kg (high, indicating extensive tissue distribution). Grazoprevir: apparent Vd approximately 19 L/kg (very high, likely due to binding to plasma proteins and tissue uptake).
Oral bioavailability: Pindolol 80-95%, Hydrochlorothiazide 65-75%.
Elbasvir: absolute bioavailability not determined in humans; oral absorption is high. Grazoprevir: absolute bioavailability approximately 27% after oral administration; absorption is enhanced with food (high-fat meal increases AUC by 1.5-fold).
Contraindicated in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment required in mild (Child-Pugh A) hepatic impairment.
Not recommended in pediatric patients (safety and efficacy not established).
Not approved for use in pediatric patients; safety and efficacy not established.
Start with lower dose (e.g., pindolol 5 mg + HCTZ 12.5 mg) due to increased sensitivity; titrate slowly. Monitor electrolytes and renal function.
No dose adjustment required; however, clinical studies indicate similar safety and efficacy as in younger adults, but caution is warranted due to potential age-related comorbidities.
Risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV, which may result in fulminant hepatitis, hepatic failure, and death. Test all patients for evidence of current or prior HBV infection before initiating treatment.
Avoid alcohol which may enhance hypotensive effects. Limit sodium intake to prevent fluid retention and counteract thiazide effect. Avoid excessive potassium intake (e.g., bananas, orange juice, salt substitutes) if using potassium-sparing adjuncts. Grapefruit juice may increase pindolol levels; avoid concurrent consumption.
ZEPATIER can be taken with or without food. No specific food restrictions are required. Grapefruit and grapefruit juice may increase exposure to grazoprevir; although not contraindicated, consider avoiding large quantities.
Pindolol and hydrochlorothiazide are excreted in breast milk. M/P ratio for pindolol ~1.0; hydrochlorothiazide ~0.2. Monitor infant for bradycardia, hypotension, and diuretic effects. Consider benefits vs risks.
No data on human milk excretion. M/P ratio unknown. Ribavirin accumulates in breast milk and is contraindicated during breastfeeding. Grazoprevir/elbasvir: animal studies show excretion in milk; potential for adverse effects. Avoid breastfeeding during treatment and for 7 days after last dose.
No specific dose adjustment established. Increase in volume of distribution and renal clearance during pregnancy may reduce drug levels; monitor efficacy and adjust as needed. Avoid hypovolemia and electrolyte imbalances.
No dose adjustment studies in pregnancy. ZEPATIER is not recommended during pregnancy due to ribavirin component. If inadvertently used, no specific dose adjustment; consult maternal-fetal specialist.
Take exactly as prescribed; do not stop abruptly due to risk of rebound hypertension or angina.,Weigh yourself daily and report rapid weight gain or swelling to your doctor.,Avoid activities requiring alertness until you know how this medication affects you.,Rise slowly from sitting or lying to prevent dizziness.,Report slow heartbeat, shortness of breath, or cold hands and feet.,Take with food or milk if stomach upset occurs.,Avoid potassium supplements or salt substitutes without consulting your doctor.
Take ZEPATIER exactly as prescribed, one tablet once daily with or without food.,Do not stop or skip doses without consulting your healthcare provider.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements, to avoid serious interactions.,Notify your healthcare provider immediately if you experience symptoms of liver problems: yellowing of skin or eyes, dark urine, pale stools, nausea, vomiting, or right upper abdominal pain.,ZEPATIER may elevate creatinine levels without reflecting kidney damage; your doctor will monitor appropriately.,If you have genotype 1a HCV, your doctor will test for specific resistance mutations to determine the correct treatment duration.,Avoid alcohol during treatment as it can exacerbate liver injury.,Use effective contraception during treatment and for 2 weeks after the last dose if you or your partner can become pregnant.